The pharmaceutical company will use IBM’s quantum computing technologies to accelerate the development of mRNA therapies and vaccines, while IBM will invest in generative AI to improve the design of those products, according to the agreement announced Thursday. (The Logic)
Talking point: IBM’s pre-trained AI model MoLFormer will help scientists predict a molecule’s properties. Moderna’s goal is to use MoLFormer to optimize the fatty nanoparticles that protect mRNA, which carries instructions to cells on how to fight diseases. IBM isn’t the only one applying AI to medicine: Toronto’s BenchSci is using AI to discover and develop drugs while Deep Genomics is using it to research gene therapy. On Wednesday, IBM posted US$14.25 billion of first-quarter revenue, weaker than analyst expectations of US$14.35 billion, but US$1.36 earnings per share exceeded expectations of US$1.26, according to Refinitiv, CNBC reported.